Gotistobart is under clinical development by OncoC4 and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gotistobart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gotistobart overview
ONC-392 is under development for the treatment of metastatic solid tumors like malignant melanoma, renal cell carcinoma, hepatocellular carcinoma, pancreatic cancer, triple negative breast cancer, non-small cell lung cancer, head and neck carcinoma, gastric carcinoma, ovarian carcinoma, cervical cancer, colorectal cancer, sarcoma, peritoneal cancer, fallopian tube cancer, adenoid cystic carcinoma, esophageal cancer, anal canal cancer, metastatic castration-resistant prostate cancer (mCRPC) and unspecified indication. The drug candidate is a monoclonal antibody. It is administered through intravenous route. It acts by targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
It was also under development for the treatment of Merkel cell carcinoma.
OncoC4 overview
OncoC4 is a clinical-stage biopharmaceutical company that discovers and develops novel biologicals to treat cancer. The company pipeline products include ONC-782, ONC-783, ONC-784, ONC-841 and A1-071 and A1-061, Its products indications comprise, advance solid tumors, non-small cell lung cancer, solid and hematologic malignancies, immune related adverse events and other oncology. OncoC4’s ONC-392, a next generation anti-CTLA-4 antibody capable of uncoupling cancer therapeutic effect from immunotherapy-related adverse effects. a humanized IgG1 monoclonal antibody enables CTLA-4 to maintain its protective function against autoimmune diseases while enhancing anti-tumor activity. OncoC4 is headquartered in Rockville, Maryland, the US.
For a complete picture of Gotistobart’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
